arrow
D

Deise Uema

daiichi sankyo company limited
H指数:9
被引数:361

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

达波替单抗德鲁克坦(Dato-DXd)的群体药代动力学分析,该药是一种TROP2靶向抗体药物偶联物,用于治疗晚期实体瘤患者。

2025-10-010
OAAI
Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05

达波替安德鲁克坦(Dato-DXd)在既往治疗过的EGFR突变型晚期非小细胞肺癌(NSCLC)患者(pts)中的有效性与安全性:TROPION-Lung01和TROPION-Lung05的合并分析

2024-12-012
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01

Datopotamab deruxtecan (Dato-DXd) 与多西他赛 (DTX) 在伴有脑转移 (mets) 的晚期非鳞状 (NSQ) 非小细胞肺癌 (NSCLC) 患者中的比较:TROPION-Lung01 研究结果

2024-09-010
PRE
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
2023-12-204
OAAI
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-11-0111
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-10-0128
PRE